| 4th Mar 2016 6:12 pm |
RNS |
Launch of Potential U.S. Public Offering of ADSs |
| 4th Mar 2016 5:54 pm |
RNS |
Fifth Filing of Form F-1 Registration Statement |
| 2nd Mar 2016 7:00 am |
RNS |
Sulfatinib Phase II initation in thyroid cancer |
| 1st Mar 2016 4:29 pm |
RNS |
Fourth Filing of Form F-1 Registration Statement |
| 1st Mar 2016 7:00 am |
RNS |
Final Results |
| 11th Feb 2016 5:39 pm |
RNS |
Public Filing of Form F-1 Registration Statement |
| 29th Jan 2016 8:03 am |
RNS |
Notice of Results |
| 15th Jan 2016 7:02 am |
RNS |
Chi-Med initiates HMPL-523 Phase I clinical trial |
| 29th Dec 2015 7:43 am |
RNS |
Blocklisting Six Monthly Return |
| 18th Dec 2015 7:00 am |
RNS |
Initiation sulfatinib Phase III registration study |
| 9th Dec 2015 7:00 am |
RNS |
US$105 m Shanghai land compensation agreement |
| 8th Dec 2015 7:00 am |
RNS |
Initiation of fruquintinib Phase 3 trial in NSCLC |
| 13th Nov 2015 2:50 pm |
RNS |
Second Public Filing of Registration Statement |
| 10th Nov 2015 1:13 pm |
RNS |
Results of Extraordinary General Meeting |
| 9th Nov 2015 7:59 am |
RNS |
Director/PDMR Shareholding |
| 6th Nov 2015 7:00 am |
RNS |
Chi-Med initiates sulfatinib U.S. clinical trials |
| 30th Oct 2015 7:00 am |
RNS |
Clinical results presented |
| 30th Oct 2015 7:00 am |
RNS |
Completion of Phase I clinical trial of HMPL 523 |
| 30th Oct 2015 7:00 am |
RNS |
Total Voting Rights |
| 20th Oct 2015 2:40 pm |
RNS |
Director's Share Dealing |
| 19th Oct 2015 7:00 am |
RNS |
Awards under Long Term Incentive Plan |
| 16th Oct 2015 12:17 pm |
RNS |
Shareholders' Circular and Notice of EGM |
| 16th Oct 2015 12:15 pm |
RNS |
Filing of Registration Statement on Form F1 |
| 16th Oct 2015 12:03 pm |
RNS |
Chi-Med files Nasdaq Registration Statement |
| 13th Oct 2015 7:00 am |
RNS |
Enrolment complete in Savolitinib Phase II trial |
| 12th Oct 2015 2:09 pm |
RNS |
Holding(s) in Company |
| 14th Sep 2015 7:00 am |
RNS |
Presentation at 2015 European Cancer Congress |
| 2nd Sep 2015 11:57 am |
RNS |
Trial of fruquintinib achieves primary endpoint |
| 19th Aug 2015 12:14 pm |
RNS |
Termination of R&D agreement with Janssen |
| 28th Jul 2015 7:00 am |
RNS |
Interim Results |
| 23rd Jul 2015 1:05 pm |
RNS |
Notification of major interest in shares |
| 23rd Jul 2015 1:01 pm |
RNS |
Notification of major interest in shares |
| 23rd Jul 2015 9:01 am |
RNS |
Mitsui exchanges shares in Hutchison MediPharma |
| 17th Jul 2015 7:00 am |
RNS |
Invention patent granted for SXBXP |
| 6th Jul 2015 7:00 am |
RNS |
Notice of Announcement of 2015 Interim Results |
| 29th Jun 2015 7:00 am |
RNS |
Blocklisting Six Monthly Return |
| 1st Jun 2015 7:00 am |
RNS |
Savolitinib preliminary Phase Ib data presented |
| 13th May 2015 7:00 am |
RNS |
Fruquintinib results trigger payments from Lilly |
| 30th Apr 2015 7:00 am |
RNS |
Total Voting Rights |
| 24th Apr 2015 12:40 pm |
RNS |
Result of AGM |
